CST3 and chronic kidney disease: In conclusion, we demonstrated that sarpogrelate and rosuvastatin could effectively ameliorate HFD/STZ-induced CKD progression by improving histopathological changes in the glomerulus and tubules, and attenuating interstitial fibrosis, albuminuria, and urinary cystatin C excretion.